疱疹样脓疱病的治疗进展

doi:10.35541/cjd.20200609

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (10): 928-931.doi: 10.35541/cjd.20200609

疱疹样脓疱病的治疗进展

邹美熔,汪盛

四川大学华西医院皮肤科，成都 610041

收稿日期:2020-06-16 修回日期:2021-01-20 发布日期:2022-10-08
通讯作者: 汪盛 E-mail:wangsheng1892@126.com
作者简介:希望在明年4月前电子版刊出。
基金资助:
四川省科技厅重点研发项目（2020YFS0197）；四川省卫健委普及应用项目（19PJ103）

Treatment of impetigo herpetiformis

Zou Meirong, Wang Sheng

Department of Dermatology, West China Hospital, Sichuan University, Chengdu 610041, China

Received:2020-06-16 Revised:2021-01-20 Published:2022-10-08
Contact: Wang Sheng E-mail:wangsheng1892@126.com
Supported by:
Key Technology R&D Program of the Science and Technology Department of Sichuan Province（2020YFS0197）; Popularized Application Project of Sichuan Provincial Health Commission （19PJ103）

摘要/Abstract

摘要： 【摘要】疱疹样脓疱病也被称作妊娠期泛发性脓疱型银屑病，通常被认为是发生于妊娠期间的脓疱型银屑病的罕见亚型。治疗方法包括系统性或局部应用糖皮质激素、环孢素、生物制剂、抗生素及光疗法、吸附分离血液粒细胞和单核细胞法等。本文综述疱疹样脓疱病的治疗进展。

关键词: 银屑病, 孕妇, 糖皮质激素类, 环孢菌素, 生物制剂, 疱疹样脓疱病

Abstract: 【Abstract】 Impetigo herpetiformis, also known as generalized pustular psoriasis of pregnancy, is generally considered as a rare subtype of pustular psoriasis that occurs during pregnancy. Current treatment includes systemic and topical glucocorticoids, cyclosporine, biologic agents, antibiotics, phototherapy, granulocyte and monocyte apheresis. This review summarizes treatment strategies for impetigo herpetiformis.

Key words: Psoriasis, Pregnant women, Glucocorticoids, Cyclosporine, Biological agents, Impetigo herpetiformis

邹美熔汪盛. 疱疹样脓疱病的治疗进展[J]. 中华皮肤科杂志, 2022,55(10):928-931. doi:10.35541/cjd.20200609

Zou Meirong, Wang Sheng. Treatment of impetigo herpetiformis[J]. Chinese Journal of Dermatology, 2022, 55(10): 928-931.doi:10.35541/cjd.20200609

参考文献 24

［1］	Fiboumi AE, Chiheb S. Impetigo herpetiformis: a rare dermotosis of pregnancy［J］. Pan Afr Med J, 2018,30:273. doi: 10.11604/pamj.2018.30.273.16424.
［2］	Tejeda CI, Voss V, Salvemini JN. Known history of pustular psoriasis with reactivation from in vitro fertilization therapy［J］. JAAD Case Rep, 2019,5（6）:543⁃545. doi: 10.1016/j.jdcr.2019. 04.005.
［3］	Namazi N, Dadkhahfar S. Impetigoherpetiformis: review of pathogenesis, complication, and treatment［J］. Dermatol Res Pract, 2018,2018:5801280. doi: 10.1155/2018/5801280.
［4］	Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives［J］. Int J Womens Health, 2018,10:109⁃115. doi: 10.2147/IJWH.S125784.
［5］	Hoegler KM, John AM, Handler MZ, et al. Generalized pustular psoriasis: a review and update on treatment［J］. J Eur Acad Dermatol Venereol, 2018,32（10）:1645⁃1651. doi: 10.1111/jdv. 14949.
［6］	Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2012,67（2）:279⁃288. doi: 10.1016/j.jaad.2011.01.032.
［7］	Chhabra G, Chanana C, Verma P, et al. Impetigo herpetiformis responsive to secukinumab［J］. Dermatol Ther, 2019,32（5）:e13040. doi: 10.1111/dth.13040.
［8］	Yamashita T, Hamada T, Maruta Y, et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare⁃up［J］. Int J Dermatol, 2019,58（3）:350⁃353. doi: 10.1111/ijd.14141.
［9］	Ogrum A, Takci Z, Seckin HY, et al. Treatment resistant impetigo herpetiformis treated with infliximab［J］. Dermatol Ther, 2019,32（2）:e12839. doi: 10.1111/dth.12839.
［10］	Babuna Kobaner G, PolatEkinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: report of a challenging case［J］. Dermatol Ther, 2020,33（4）:e13571. doi: 10.1111/dth.13571.
［11］	Burmester GR, Landewé R, Genovese MC, et al. Adalimumab long⁃term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis［J］. Ann Rheum Dis, 2017,76（2）:414⁃417. doi: 10.1136/annrheumdis⁃2016⁃209322.
［12］	Flynn A, Burke N, Byrne B, et al. Two case reports of generalized pustular psoriasis of pregnancy: different outcomes［J］. Obstet Med, 2016,9（2）:55⁃59. doi: 10.1177/1753495X15626623.
［13］	Gordon KB, Warren RB, Gottlieb AB, et al. Long⁃term efficacy of certolizumabpegol for the treatment of plaque psoriasis: 3⁃year results from two randomized phase Ⅲ trials （CIMPASI⁃1 and CIMPASI⁃2）［J］. Br J Dermatol, 2020. doi: 10.1111/bjd.19393.
［14］	Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study［J］. Ann Rheum Dis, 2018,77（2）:228⁃233. doi: 10.1136/annrheumdis⁃ 2017⁃212196.
［15］	Liu N, Zhu L, Cheng Y, et al. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report［J］. Acta Derm Venereol, 2020,100（15）:adv00251. doi: 10.2340/ 00015555⁃3611.
［16］	Mizutani Y, Mizutani YH, Matsuyama K, et al. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumabpegol［J］. J Dermatol, 2020,47（7）:e262⁃e263. doi: 10.1111/1346⁃8138.15355.
［17］	Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database［J］. Br J Dermatol, 2018,179（5）:1205⁃1207. doi: 10.1111/bjd.16901.
［18］	Kinoshita M, Ogawa Y, Takeichi T, et al. Impetigo herpetiformis with IL⁃36RN mutation successfully treated with secukinumab［J］. Eur J Dermatol, 2018,28（3）:381⁃382. doi: 10.1684/ejd. 2018.3259.
［19］	Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis［J］. J Eur Acad Dermatol Venereol, 2016,30（3）:488⁃490. doi: 10.1111/jdv.12872.
［20］	Mizutani Y, Fujii K, Kawamura M, et al. Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis［J］. J Dermatol, 2020,47（11）:1326⁃1329. doi: 10.1111/1346⁃8138.15569.
［21］	Fujii K, Takahashi T, Matsuyama K, et al. Impetigo herpetiformis with a CARD14 Thr79Ile variant successfully treated with granulocyte and monocyte adsorption apheresis［J］. J Dermatol, 2020,47（3）:e84⁃e85. doi: 10.1111/1346⁃8138.15241.
［22］	Saito⁃Sasaki N, Izu K, Sawada Y, et al. Impetigo herpetiformis complicated with intrauterine growth restriction treated successfully with granulocyte and monocyte apheresis［J］. Acta Derm Venereol, 2017,97（3）:410⁃411. doi: 10.2340/00015555⁃2527.
［23］	Luewan S, Sirichotiyakul S, Tongsong T. Recurrent impetigo herpetiformis successfully treated with methotrexate: a case report［J］. J ObstetGynaecol Res, 2011,37（6）:661⁃663. doi: 10. 1111/j.1447⁃0756.2010.01418.x.
［24］	Cravo M, Vieira R, Tellechea O, et al. Recurrent impetigo herpetiformis successfully treated with methotrexate［J］. J Eur Acad Dermatol Venereol, 2009,23（3）:336⁃337. doi: 10.1111/j.1468⁃3083.2008.02867.x.

[1]	肖春英王刚. 朗格汉斯细胞在银屑病中的作用研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 830-834.
[2]	郑佳媛余炳前陈显侠骆志成. 成人寻常型银屑病瘙痒特征及对生活质量的影响调查[J]. 中华皮肤科杂志, 2022, 55(9): 790-794.
[3]	周雪, 余增洋, 陈有东, 郭春源, 于倩, 胡艺凡, 姚玲玲, 史玉玲, . 肿瘤坏死因子α介导银屑病脂肪酸去饱和酶2低表达[J]. 中华皮肤科杂志, 2022, 55(9): 752-758.
[4]	姚玲玲, 余增洋郭春源周静崔莲于倩虞英媛周雪蔡江鲁伊史玉玲, . 节律基因隐花色素2在银屑病小鼠模型及HaCaT细胞中的表达变化及机制研究[J]. 中华皮肤科杂志, 2022, 55(9): 759-766.
[5]	俞晨王刚. [开放获取] 小分子靶向药物：银屑病治疗的新选择[J]. 中华皮肤科杂志, 2022, 55(9): 747-751.
[6]	孙杰王睿李承新. 肿瘤坏死因子α抑制剂诱导的银屑病研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 821-824.
[7]	刘晋沈征宇. 银屑病表观遗传调控的研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 825-829.
[8]	樊碧娆陈喜雪王明悦. [开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(8): 676-681.
[9]	晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739.
[10]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[11]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[12]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[13]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[14]	赵柳琦陈妍陈丹阳樊碧娆王瑞尚盼盼陈喜雪朱学骏王明悦. 【开放获取】度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(6): 480-485.
[15]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.

疱疹样脓疱病的治疗进展

Treatment of impetigo herpetiformis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

Metrics

本文评价

推荐阅读 10